Literature DB >> 10956652

The relaxin receptor-binding site geometry suggests a novel gripping mode of interaction.

E E Büllesbach1, C Schwabe.   

Abstract

Relaxin has a unique, clearly identifiable, mixed function receptor-binding region comprising amino acid residues that evolve sequentially from the central portion of the B chain alpha-helix. Two arginine residues in positions B13 and B17 that project like forefinger and middle finger from the helix provide the electrostatic element opposed by the hydrophobic (thumb) element isoleucine (B20), offset from the arginines by about 40 degrees. The binding intensity of relaxin to its receptor decreases by 3 orders of magnitude if alanine is substituted for the newly discovered binding component isoleucine in position B20. The arginine residues cannot be replaced by other positive charges, nor can the guanidinium group be presented on a longer or shorter hydrocarbon chain. In contrast, the hydrophobic interaction is incremental in nature, and the contribution to the total binding energy is roughly proportional to the number of hydrocarbon units in the side chain. It appears that a hydrophobic surface exists on the receptor that offers optimal van der Waals' interaction with beta-branched hydrophobic amino acids. The binding energy increases roughly 10-fold with each methylene group whereby beta-branching is more effective per surface unit than chain elongation. Aromatic side chains appear to demarcate the extent of the binding region in so far as residues larger than phenylalanine decrease receptor binding. The exceptional clarity of binding site geometry in relaxin makes for an excellent opportunity to design peptido-mimetics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10956652     DOI: 10.1074/jbc.M005728200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  New Insights into biological roles of relaxin and relaxin-related peptides.

Authors:  Jae-Il Park; Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

Review 2.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

3.  The minimal active structure of human relaxin-2.

Authors:  Mohammed Akhter Hossain; K Johan Rosengren; Chrishan S Samuel; Fazel Shabanpoor; Linda J Chan; Ross A D Bathgate; John D Wade
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

Review 4.  Relaxin family peptides: structure-activity relationship studies.

Authors:  Nitin A Patil; K Johan Rosengren; Frances Separovic; John D Wade; Ross A D Bathgate; Mohammed Akhter Hossain
Journal:  Br J Pharmacol       Date:  2017-01-19       Impact factor: 8.739

Review 5.  Relaxin family peptide systems and the central nervous system.

Authors:  G E Callander; R A D Bathgate
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

6.  Identification of key residues essential for the structural fold and receptor selectivity within the A-chain of human gene-2 (H2) relaxin.

Authors:  Linda J Chan; K Johan Rosengren; Sharon L Layfield; Ross A D Bathgate; Frances Separovic; Chrishan S Samuel; Mohammed A Hossain; John D Wade
Journal:  J Biol Chem       Date:  2012-09-28       Impact factor: 5.157

Review 7.  Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain.

Authors:  Sherie Ma; Craig M Smith; Anna Blasiak; Andrew L Gundlach
Journal:  Br J Pharmacol       Date:  2016-12-04       Impact factor: 8.739

8.  Investigation of interactions at the extracellular loops of the relaxin family peptide receptor 1 (RXFP1).

Authors:  Natalie A Diepenhorst; Emma J Petrie; Catherine Z Chen; Amy Wang; Mohammed Akhter Hossain; Ross A D Bathgate; Paul R Gooley
Journal:  J Biol Chem       Date:  2014-10-28       Impact factor: 5.157

9.  Structure of the R3/I5 chimeric relaxin peptide, a selective GPCR135 and GPCR142 agonist.

Authors:  Linda M Haugaard-Jönsson; Mohammed Akhter Hossain; Norelle L Daly; Ross A D Bathgate; John D Wade; David J Craik; K Johan Rosengren
Journal:  J Biol Chem       Date:  2008-06-24       Impact factor: 5.157

10.  Evolution of the relaxin-like peptide family.

Authors:  Tracey N Wilkinson; Terence P Speed; Geoffrey W Tregear; Ross A D Bathgate
Journal:  BMC Evol Biol       Date:  2005-02-12       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.